Structure Therapeutics is a ‘no-brainer takeout’ target, says Mizuho’s Jared Holz

June 3, 2024
Structure Therapeutics is a ‘no-brainer takeout’ target, says Mizuho’s Jared HolzStructure Therapeutics is a ‘no-brainer takeout’ target, says Mizuho’s Jared Holz

Jared Holz, Mizuho, joins ‘Fast Money’ to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.


 

Share This

Latest Mizuho News

Mizuho Americas and NPower Advance Tech Career Pathways for New Yorkers Through Path2TECH: NetSA

Mizuho Americas and NPower Advance Tech Career Pathways for New Yorkers Through Path2TECH: NetSA

January 8, 2026
Mizuho Americas announces $1 million in grants through the Mizuho USA Foundation

Mizuho Americas announces $1 million in grants through the Mizuho USA Foundation

January 5, 2026
Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein

Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein

November 18, 2025

Mizuho news from around the globe

back-to-top-blue